Journal
JOURNAL OF CHILD NEUROLOGY
Volume 29, Issue 9, Pages 1235-1240Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0883073814538509
Keywords
Bendavia; coenzyme q10; epi-743; epicatechin; mitochondrial disease; therapies; vitamins
Categories
Funding
- Edison Pharmaceuticals, Inc.
- National Institute of Neurological Disorders Stroke [R13 NS040925]
Ask authors/readers for more resources
Although mitochondrial disorders are among the most common inherited conditions that cause neurologic impairment, there are currently no US Food and Drug Administration (FDA)-approved medications designed to treat primary mitochondrial disease. This is in part related to the lack of biomarkers to monitor disease status or response to treatment and the paucity of randomized, controlled clinical trials focused on mitochondrial disease therapies. Despite this discouraging historical precedent, a number of new approaches to mitochondrial disease therapy are on the horizon. By studying metabolites central to redox chemistry, investigators are gaining new insights into potential noninvasive biomarkers. Controlled clinical trials designed to study the effects of novel redox-modulating therapies, such as EPI-743, in patients with inherited mitochondrial disease are also underway. Furthermore, several new compounds with potential effects on inner mitochondrial membrane function and mitochondrial biogenesis are in development. Such advances are providing the foundation for a new era in mitochondrial disease therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available